# Understanding the 340B PATIENTS Act of 2024

The 340B drug discount program is a federal initiative that requires pharmaceutical manufacturers to sell certain drugs at deeply discounted prices to hospitals, clinics, and health centers that serve low-income and uninsured patients. This bill clarifies and strengthens how that program works, particularly when these healthcare facilities partner with pharmacies to distribute discounted medications.

Here's the core issue the bill addresses: Some drug manufacturers have been trying to restrict how covered entities (hospitals and clinics) can use their 340B discounts. Specifically, manufacturers have been refusing to sell discounted drugs to pharmacies that work on behalf of these healthcare facilities, or they've been placing conditions on where and how the drugs can be dispensed. This creates a real problem because many patients need specialty drugs—like cancer medications or treatments for rheumatoid arthritis—that are only available through specialty pharmacies located far from their local clinic. When manufacturers block these arrangements, patients can't access the discounted medications they need, and hospitals lose the savings they're supposed to use to expand care and services to their communities.

This bill makes clear that drug manufacturers cannot place these kinds of restrictions. It explicitly states that manufacturers must offer 340B pricing regardless of whether a drug is dispensed directly by a hospital or through a contracted pharmacy. The bill also establishes real consequences for manufacturers who violate these rules—they can face civil penalties up to $2 million per day of violation. Additionally, it gives the federal government authority to approve any conditions manufacturers want to impose, ensuring that restrictions don't undermine the program's core purpose of helping healthcare facilities stretch their resources to serve more patients and provide better care.